MAPT and progressive supranuclear palsy: Additionally, they were able to provide an interpretation of the classification, which included different structural patterns in the immunoreactivity of the Tau protein in NFTs present in the brains of patients with progressive supranuclear palsy and Alzheimer’s disease [79].